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Liver cancerAbstract Purpose: In 2015, we published a study on a small series of patients with hepato-
cellular carcinoma (HCC) treated chronically with metformin for type II diabetes mellitus
(DM2) who showed a poorer response to sorafenib. The aim of the present study was to vali-
date the prognostic significance of metformin in HCC patients treated with sorafenib,
providing a biological rationale for the mechanism of resistance to sorafenib in patients on
chronic metformin therapy, and to clarify the role of sirtuin-3 (SIRT-3), a protein involved
in metabolic diseases and acknowledged as a tumour suppressor in HCC, in this resistance.
Patients and methods: We analysed 279 patients consecutively treated with sorafenib for the
clinical analysis. Of the 86 (30%) patients with DM2, 52 (19%) were on chronic treatment with
metformin and 34 (12%) with insulin. We included 43 patients with HCC for the biological
study: 19 (44.1%) were diabetic and 14 (73.7%) of these received metformin for DM2.
SIRT-3 expression was investigated by immunohistochemistry (IHC) in formalin-fixed and
paraffin-embedded (FFPE) samples.
Results: InHCC patients undergoing chronic treatment withmetformin, the use of sorafenib was
associated with poor progression-free survival (PFS) and overall survival (OS) (1.9 and 6.6
months, respectively) compared to 3.7months and 10.8months, respectively, for patients without
DM2 and 8.4 months and 16.6 months, respectively, for patients on insulin (P < .0001). We also
observed that SIRT-3 protein expression was significantly higher in patients treated with metfor-
min than in those not taking this medication (65% versus 25%, respectively) (PZ .013).
Conclusions: Our findings could be attributed to increased tumour aggressiveness and resistance
to sorafenib caused by chronic treatment with metformin.
ª 2017 Elsevier Ltd. All rights reserved.1. Introduction
Hepatocellular carcinoma (HCC) is the fifth most
common cancer worldwide in men and the second most
frequent cause of cancer-related deaths [1e3]. Each year
it is diagnosed in more than 500,000 people worldwide.
The decrease in virus-associated HCC observed in Italy
in recent years has been offset by an increase in HCC
caused by non-alcoholic fatty liver disease (NAFLD)
[4,5]. It has been seen that the use of sorafenib increases
median overall survival of HCC patients (10.7 months
for sorafenib group versus 7.9 months for placebo
group), representing a 31% decrease in the relative risk
of death [6]. However, there is still no validated bio-
logical or clinical marker that predicts response to
treatment in these patients [7e12].
In 2015, we published a study on a series of HCC
patients who showed a poorer response to sorafenib as a
result of chronic treatment with metformin for type II
diabetes mellitus (DM2) [13]. The patients who devel-
oped HCC whilst undergoing chronic therapy with
metformin showed a median progression-free survival
(PFS) of 2.6 months compared to 5.0 months for those
not taking this medication. Overall survival (OS) was
10.4 months and 15.1 months, respectively.
Sirtuin-3 (SIRT-3), one of the evolutionarily conserved
mammalian orthologues of the silent information regu-
lator 2 (Sir2) is a nicotinamide adenine dinucleotide
(NAD)þ-dependent deacetylase involved in regulating
mitochondrial metabolism [14]. Its regulatory effects andinvolvement in metabolic diseases are believed to have a
strong impact on the development and treatment of HCC.
Although the reported evidences suggest a putative bridge
role of SIRT-3 between metabolic disorders and HCC,
further studies are necessary to demonstrate such inter-
connection [15,16]. The aim of the present study was to
validate the prognostic significance of metformin and in-
sulin in HCC patients treated with sorafenib, and to
establish a biological rationale for the mechanism
involved in resistance to sorafenib in those undergoing
chronic metformin therapy.
2. Patients and methods
2.1. Patient population for the clinical study
The present study was performed using the medical re-
cords from the databases of Istituto Scientifico
Romagnolo per lo Studio e la Cura dei Tumori (IRST)
IRCCS (Meldola); Department of Medical Oncology,
University of Cagliari; Universita` Campus Bio-Medico
(Rome); National Cancer Institute ‘Giovanni Paolo II’
(Bari), University of Bari Medical School; and San-
t’Orsola-Malpighi Hospital, University of Bologna.
Data were entered into electronic data files by co-
investigators from each centre taking part and checked
at the data management centre for missing information
and internal consistency. The study protocol was
reviewed and approved by the local Ethics Committee.
All patients gave their written informed consent.
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twice daily) for advanced or intermediate-stage HCC
(either histologically proven or diagnosed according to
the AASLD [American Association for the Study of
Liver Diseases 2005] guidelines) that was refractory or
no longer amenable to locoregional therapies. Eligibility
criteria were the same as those of Llovet’s pivotal study
on sorafenib in HCC [5]. Dose reductions were applied
when clinically indicated. Follow-up consisted of a
computed tomography (CT)/magnetic resonance imag-
ing (MRI) scan every 8 weeks or as clinically indicated.
Tumour response was evaluated in accordance with
modified Response Evaluation Criteria in Solid Tu-
mours (mRECIST) [17]. Treatment with sorafenib was
continued until disease progression, unacceptable
toxicity or death.
We defined ‘patients with diabetes and treated with
metformin’ as those who had been taking metformin for
at least 5 years at the time of the first diagnosis of HCC.
‘Patients with diabetes and treated with insulin’ were
defined as those who had been taking insulin for at least
5 years when HCC was first diagnosed.
The primary objective of this study was to compare
PFS in patients taking metformin or insulin or no
antidiabetic medication at the time of the first diagnosis
of HCC. The second objective was to compare OS in the
same patients.
2.2. Patient population for SIRT-3 evaluation
The study was performed on biopsies obtained from 46
patients with early stage HCC treated with curative
hepatic resection in the Departments of General Sur-
gery, Morgagni-Pierantoni Hospital (AUSL Romagna,
Forli, Italy) and Universita` Campus Bio-Medico
(Rome, Italy). Eligibility criteria were: Child Pugh A,
Barcelona clinic liver cancer (BCLC) stage 0 or BCLC
A; The BCLC staging classification links the stage of the
disease to a specific treatment strategy. We excluded the
patients with incomplete clinical data.
SIRT-3 expression was evaluated by immunohisto-
chemistry (IHC) in formalin-fixed paraffin-embedded
(FFPE) samples using a rabbit monoclonal antibody
directed against SIRT-3 (Abcam: Clone C73E3) and the
Ventana Optiview DAB IHC detection kit on a Ventana
Benchmark XT automated system. Marker expression
was recorded as the percentage of positive tumour cells
in relation to the overall neoplastic population.
2.3. Statistical analysis of the clinical study
The patient population was divided into three groups
for the clinical study on the basis of the presence of
diabetes and the type of antidiabetic treatment received
(no diabetes, diabetes with metformin, diabetes with
insulin). PFS was calculated from the day of the start of
treatment until the day of disease progression or lastfollow-up. OS was calculated from the day of the start
of treatment until the day of death or last follow-up.
Patients lost to follow-up were censored at the time of
the last contact. Descriptive data were reported as
median with range for continuous variables, and ab-
solute and relative frequencies for categorical variables.
The association among the categorical variables was
analysed by the chi-squared test. Survival distribution
was estimated by the KaplaneMeier method. Signifi-
cant differences in probability of relapsing between the
strata were evaluated by the log-rank test. Cox multiple
regression analysis was used to assess the role of vari-
ables that proved significant in univariate analysis. A P
value < .05 was considered statistically significant in all
analyses.
Tested variables included gender (male versus fe-
male), age (68 years versus >68 years), cirrhosis aeti-
ology (hepatitis C infection versus hepatitis B infection
versus alcoholic, metabolic or cryptogenic), Eastern
Cooperative Oncology Group (ECOG) performance
status (ECOG PS: 0 versus 1 versus 2), Barcelona Clinic
Liver Cancer (BCLC) stage (B versus C), Child-Pugh
class (A versus B), extrahepatic spread (yes versus no),
portal vein thrombosis (yes versus no), median alpha-
fetoprotein (AFP) serum level (37 ng/ml
versus > 37 ng/ml), previous treatments received (no
other treatments versus surgery alone versus interven-
tional procedures alone versus surgery and interven-
tional procedures). MedCalc package (MedCalc
version 16.8.4) was used for all statistical analysis.2.4. Statistical analysis of the SIRT-3 evaluation
Descriptive statistics (median and range of variation
were used to analyse SIRT-3), considered as a contin-
uous variable. A comparison of median values of SIRT-
3, depending on the different clinical features, was per-
formed using the non-parametric Wilcoxon test. All P
values were obtained from two-tailed tests, and statis-
tical analyses were performed with SAS statistical soft-
ware, version 9.4 (SAS Institute, Cary, NC, United
States of America).3. Results
3.1. Patient characteristics
Two hundred and seventy-nine patients (237 males and
42 females) with HCC, consecutively treated with sor-
afenib from May 2007 to September 2015, were
included in the clinical study. Median age was 69 years
(range 28e88 years). Two hundred and sixty-two pa-
tients had Child-Pugh A HCC, and 17 had Child-Pugh
B HCC. Seventy-seven patients had BCLC-B, and 202
patients had BCLC-C. The most common aetiologies of
liver disease were hepatitis C (58%), alcohol-derived
Table 2
Patient characteristics in the biological study.
Patients No. (%)
Median age, years [range] 70 [45e87]
Gender
Male 36 (83.7)
Female 7 (16.3)
Etiology
Hepatitis C 20 (46.5)
Metabolic liver disease 16 (37)
Alcoholic liver disease 7 (16.2)
BCLC-A 43 (100)
Child-Pugh A 43 (100)
Diabetes mellitus
Yes 19 (44.1)
No 24 (55.9)
Taking metformin
Yes 14 (32.5)
No 29 (67.5)
BCLC, Barcelona Clinic Liver Cancer.
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atitis B (13%) and cryptogenic aetiology (7%). Eighty-
six (30%) patients had DM2, of whom 52 (19%) were
on treatment with metformin and 34 (12%) with
insulin.
With the exception of the cirrhosis aetiology, the
three groups of patients were comparable for all major
clinical characteristics investigated (Table 1). Metabolic
liver disease was more frequent in patients with DM2
undergoing treatment with either metformin or insulin
than in non-diabetic patients in whom, conversely, viral
infection was predominant (metabolic aetiology: DM2
receiving insulin treatment, 44%; DM2 receiving met-
formin treatment, 27%; no DM2, 1%).
Forty-three patients (36 males and 7 females) with
HCC, consecutively treated with surgery during the
period from April 2001 to May 2015, were included in
the biological study. Median age was 70 years (range
45e87 years). All patients had Child-Pugh A and
BCLC-A. The most common aetiologies of liver disease
were hepatitis C (46.5%), alcoholic liver disease (16.2%)
and metabolic liver disease (37%). Nineteen (44.1%)
patients were diabetic, and 14 (73.7%) of these were
undergoing treatment with metformin (Table 2).Table 1
Patient characteristics in the clinical study population.
Patients Diabetes mellitus
type II treated with
metformin
No diabe
No. % No.
Gender
Male 46 88 160
Female 6 12 33
Median age, years (range)
>69 29 56 90
69 23 44 103
Cirrhosis aetiology
HCV 23 44 132
HBV 2 4 34
Alcohol 8 15 16
Cryptogenic 5 10 10
Metabolic 14 27 1
ECOG PS
0 24 46 117
1e2 28 54 76
BCLC stage
B 14 27 47
C 38 73 146
Extrahepatic metastasis
Yes 21 40 93
No 31 60 100
Portal thrombosis
Yes 17 33 69
No 35 67 124
Median AFP level
>37 22 42 100
37 30 58 93
Total no. 52 193
HCV, hepatitis C virus; HBV, hepatitis B virus; BCLC, Barcelona Clinic L3.2. Treatment with metformin or insulin and clinical
outcome
The median PFS of all patients was 3.6 months (95% CI:
3.1e4.4) and median OS was 10.7 months (95% CI:tes Diabetes mellitus
type II treated with
insulin
P
% No. %
83 31 91 .339
17 3 9
47 19 56 .367
53 15 44
68 8 24 <.0001
18 1 3
8 7 20
5 3 9
1 15 44
61 25 74 .103
39 9 26
24 15 44 .058
76 19 56
48 11 32 .179
52 23 68
36 7 21 .223
64 27 79
52 12 35 .135
48 22 65
34
iver Cancer; AFP, alpha-fetoprotein.
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chronic treatment with metformin was associated with a
median PFS of 1.9 months (95% CI 1.8e2.3) compared
to 3.7 months (95% CI 3.1e4.6) for non-diabetic pa-
tients and 8.5 months (95% CI 5.3e11.4) for those on
insulin (P < .0001) (Fig. 1A).
Metformin-treated patients showed a median OS of
6.6 months (95% CI 4.6e8.7) compared to 10.8 months
(95% CI 9.0e13.1) for non-diabetic patients 16.6
months (95% CI 14.5e25.5) for the insulin group
(P Z .0001) (Fig. 1B).
Conversely, no differences in survival were observed
between the overall DM2 population and the non-dia-
betic group. PFS (P Z .471): DM2 (3.2 months) versus
no DM2 (3.7 months). OS (P Z .734): DM2 (10.7
months) versus no DM2 (10.8 months).
Of the clinical variables tested in univariate analysis,
ECOG PS (P Z .0034) and BCLC stage (P Z .0336)
were predictive of PFS. ECOG PS (P < .0001) and
median AFP serum levels (PZ .0145) were predictive of
OS. In particular for PFS: ECOG PS 0 (4.4 months, 95%
CI 3.5e5.2) versus 1e2 (2.9 months, 95% CI 2.6e3.7);
and BCLC stage B (5.7 months, 95% CI 4.5e6.7) versus
C (3.1 months, 95% CI 2.7e3.7). For OS: ECOG PS
0 (14.3 months, 95% CI 11.9e15.5) versus 1e2 (7.9
months, 95% CI 6.8e9.1); and median AFP serum
level  37 ng/ml (10.9 months, 95% CI 9.4e15.0) versus
>37 ng/ml (10.2 months, 95% CI 8.1e13.1). In multi-
variate analysis the DM2 profile (DM2 metformin
versus no DM2 versus DM2 insulin) maintained an in-
dependent prognostic value for PFS (P < .0001).
Conversely, ECOG PS, median AFP serum level and
DM2 profile maintained an independent prognostic
value for OS (P < .0001). All of the other clinical vari-
ables failed to show any correlation with patient
outcome.Fig. 1. KaplaneMeier curves. A) Progression-free survival (PFS) and B
diabetes; dashed line, diabetes metformin.The effect of metformin on clinical outcome was also
investigated in relation to the objective response rate
(ORR). Patients treated chronically with metformin
showed a higher percentage of progression at the first
CT re-evaluation than those treated with insulin or the
non-diabetic group (75.8% versus 14.7% versus 38.8%,
respectively).
Considering the overall population, the probability of
progression was higher in DM2 patients taking met-
formin than in the non-diabetic group (hazard ratio,
HR Z 1.91, 95% CI 1.28e2.8). Similar results were
observed for survival (HR Z 1.70, 95% CI 1.14e2.55).
The risk of progression was lower in DM2 patients
taking insulin than in non-diabetic patients (HR Z .65,
95% CI 0.48e.89). Similar results were observed for
survival (HR Z .62, 95% CI 0.44e.87).
With regard to diabetic patients, the risk of pro-
gression was higher in those taking metformin than in
the insulin group (HR: 2.91; 95% CI: 1.84e4.6). Similar
results were observed for survival (HR: 2.74; 95% CI:
1.69e4.43).
Significant differences in the toxicity profile were
found in the three patient groups (Supplementary
Table S1).
3.3. Immunohistochemical expression of SIRT-3 in HCC
patients
We studied the functional status of SIRT-3 enzyme in
HCC samples by determining the immunohistochemical
expression of its short isoform, relocated in the mito-
chondria. A representative case of SIRT-3 staining is
shown in Fig. 2. SIRT-3 was expressed in the majority of
cases, with a range of positivity in the neoplastic pop-
ulation varying from 0% to 90% and a median value of
40% of malignant cells (Table 3).) overall survival (OS). Solid line, diabetes insulin; dotted line, no
Fig. 2. Immunohistochemical staining for SIRT-3. A) SIRT-3
expression in patients with early stage HCC after surgery and B)
SIRT-3 expression in HepG2 cell line used as positive control.
Table 3
Comparison between median values of SIRT-3 short expression
and clinical characteristics.
Median percentage
expression of short
form of SIRT-3 (range)
P
Etiology
Metabolic syndrome 60 (10e90)
Other 30 (0e90) .044
Diabetes mellitus
Yes 55 (10e90)
No 25 (0e90) .013
Taking metformin
Yes 65 (10e90)
No 25 (0e90) .013
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This subgroup showed a significantly higher expression
of SIRT-3 than patients with different aetiology (me-
dian 60% versus 30%, respectively). The higher expres-
sion of the protein correlated significantly with the
presence of DM2 (median value 55% in diabetic patients
versus 25% in non-diabetic patients) (P Z .013) (Table
3). Interestingly, SIRT-3 protein expression was also
higher in patients treated with metformin than in those
taking insulin (65% versus 25%, respectively) (PZ .013)
(Table 3).
4. Discussion
In the present study, we validated the association be-
tween metformin, insulin and sorafenib in HCC pa-
tients. Our findings highlighted a lower response to
sorafenib in those who developed HCC whilst under-
going chronic therapy with metformin. In contrast to
our first study [13], HCC patients on chronic insulin
therapy showed a better response to treatment and
longer survival. We hypothesised that the discrepancy in
reported results may be justified by the different number
of patients enrolled in the two studies. Indeed, in the
first, we analysed few cases and the data were not sig-
nificant; on the contrary in this actual study, we enrolled
the greater number of patients obtaining promising
results.The population analysed was homogeneous for age,
sex, ECOG Performance status, BCLC stage, presence of
extrahepatic metastases, portal thrombosis, previous
treatments and baseline levels of a-fetoprotein, but not
for aetiology. This aetiological non-homogeneity can be
attributed to the expected greater frequency of diabetes in
patients with metabolic liver disease. In addition, we also
reported an increased toxicity in patients treated with
insulin, probably related to the most significant response
in patients with increased sorafenib toxicity [12,18].
Metformin has been shown to inhibit tumour growth
in vitro and in vivo by inducing apoptosis in various
cancers [19e21]. Retrospective studies also suggest that
metformin prevents HCC development in individuals
with diabetes and in diabetic patients with chronic liver
disease [22e26]. A large population-based study by
Chen et al. [22] demonstrated a dose-dependent decrease
in the risk of HCC among diabetic patients. A recent
meta-analysis confirmed a 50% decrease in HCC inci-
dence among diabetics on metformin but also revealed a
significant increase in the risk of HCC in insulin-treated
patients [27]. A possible explanation for these contra-
dictory results is that tumours developing during
chronic treatment with metformin have intrinsic mech-
anisms of resistance to metformin, which may also lead
to resistance to sorafenib.
Recently, Di Costanzo et al. reported an increase in
time to progression and OS in HCC patients with dia-
betes compared to those without diabetes [28]. However,
the authors did not distinguish between different hypo-
glycaemic therapies used. Conversely, we did not
observe any significant difference in the aforementioned
parameters between diabetic and non-diabetic patients.
Our results could be potentially attributed to increased
tumour aggressiveness and resistance to sorafenib in
patients treated with metformin compared to insulin or,
from a biological point of view, to different molecular
mechanisms of the antidiabetic drugs.
It has been demonstrated that metformin activates
liver kinase B1 (LKB1) and AMP-activated protein ki-
nase (AMPK), leading to mammalian or mechanistic
target of rapamycin (mTOR) inhibition and cell growth
arrest [29]. The inhibition of mTOR can also be induced
directly by hypoxia-induced factor-1a (HIF-1a) repres-
sion via AMPK [30,31] or indirectly by SIRT-3-
mediated HIF-1a inhibition [32].
Starting from the evidence that SIRT-3 represents a
critical effector in AMPK/HIF-1a/mTOR pathway and
in line with the elucidated mechanism, we focussed our
attention on SIRT-3 in HCC patients in chronic treat-
ment with metformin. Interestingly, we observed that its
expression significantly increased in this setting of pa-
tients and this rise correlated with the presence of
metabolic syndrome and DM2, suggesting an important
role of SIRT-3 in metabolic disorders.
Metformin can also bypass AMPK, directly inhibit-
ing mTOR signalling and inducing cell cycle arrest by
A. Casadei Gardini et al. / European Journal of Cancer 86 (2017) 106e114112cyclin D1 downregulation via p53 [33,34]. Conversely,
insulin exerts a proliferative effect directly through the
insulin receptor, leading to the activation of phosphoi-
nositide 3-kinase (PI-3K) and mitogen-activated protein
kinase (MAPK) pathways, and indirectly through an
increase in circulating levels of insulin growth factor-1
(IGF-1) [35]. When blood glucose levels go up, insulin
metabolic activity decreases, leading to the over-
activation of mTOR, which in turn downregulates in-
sulin signal-related metabolic pathways. In contrast,
insulin induces the MAPK pathway, enhancing cell
survival [36]. As shown in Fig. 3, metformin suppresses
PI-3K and MAPK signal cascades (both of which are
targets of sorafenib), directly via IGF or mTOR sig-
nalling inhibition or indirectly via AMPK pathway. We
hypothesise that patients on chronic treatment with
metformin develop resistance to sorafenib because the
above pathways are already blocked.
One strength of our study lies in the detailed infor-
mation it provides on patient characteristics and follow
up. However, there are also some limitations, i.e. despite
being a retrospective evaluation, cases were selected
consecutively to minimise bias. Regarding the biological
part, we are aware that the only evaluation of SIRT-3 is
not exhaustive to justify the putative mechanism of
resistance to sorafenib in patients treated chronicallyFig. 3. Mechanisms of action of sorafenib and metformin awith metformin. However, supported by the literature,
our explanation can represent a start point to expand
our understanding on SIRT-3 bridge role among meta-
bolic dysfunctions, metformin and HCC.
Overall, our results confirmed a resistance to sor-
afenib in patients who develop HCC during treatment
with metformin. Conversely, insulin-treated patients
showed a better response and longer survival. Our
findings also reveal different tumour biology between
the various aetiologies of HCC and we hypothesise that
SIRT-3 could play a fundamental role in the develop-
ment of resistance to sorafenib. Future research should
focus on identifying personalized treatments based on
aetiology and different tumour biology.
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